Beyondspring Inc (NASDAQ:BYSI)’s share price rose 5.3% on Friday . The stock traded as high as $23.92 and last traded at $23.70. Approximately 1,288,058 shares were traded during mid-day trading, an increase of 4,822% from the average daily volume of 26,168 shares. The stock had previously closed at $22.50.
BYSI has been the subject of several research reports. HC Wainwright reissued a “buy” rating on shares of Beyondspring in a report on Monday, March 4th. Maxim Group downgraded Beyondspring from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th.
The company’s fifty day moving average price is $17.50.
Beyondspring Company Profile (NASDAQ:BYSI)
BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.
Further Reading: What Are Cryptocurrencies?
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.